Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders, with a primary emphasis on its product candidate, Neflamapimod. The company has completed enrollment in a Phase 2a study for the treatment of non-fluent variant primary progressive aphasia and is preparing for a pivotal trial to assess Neflamapimod in patients with dementia with Lewy bodies. Additionally, CervoMed has plans to start a clinical study for Neflamapimod in amyotrophic lateral sclerosis by the end of this year.

Bears say

CervoMed is facing significant challenges moving forward, as evidenced by their recent financial performance and the failure of their drug candidate, Neflamapimod, to replicate positive results in their Phase 2a study. The data shows that the drug was not effective in patients with Alzheimer's co-pathology and lower-than-expected drug exposure. Additionally, their current valuation is based on optimistic assumptions, and there are numerous risks that could hinder their success, including delays in their Phase 3 trial and failure to secure regulatory approval.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.